Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc.
Go back to Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc.| Merck & Co. (NYSE: MRK) | Delayed: 149.80 +2.04 (1.38%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $147.76 | 52 Week High | $65.46 | |||
| Open | $150.23 | 52 Week Low | $47.97 | |||
| Day High | $151.68 | P/E | 101.90 | |||
| Day Low | $148.55 | EPS | $1.47 | |||
| Volume | 5,440,079 | |||||
| IGNYTA (NASDAQ: RXDX) | Delayed: 199.92 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $199.92 | 52 Week High | $15.20 | |||
| Open | $10.02 | 52 Week Low | $4.15 | |||
| Day High | $199.92 | P/E | N/A | |||
| Day Low | $199.92 | EPS | $-0.44 | |||
| Volume | 417,305 | |||||
